Search Result

Pathways Recommended:	Cell Cycle/DNA Damage

Results for "

bacterial DNA gyrase

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Bacterial (78) DNA Glycosylase (1) DNA/RNA Synthesis (39) Antibiotic (44) Apoptosis (2) Cytochrome P450 (1) Dihydrofolate reductase (DHFR) (1) Drug Derivative (1) Drug Metabolite (4) Endogenous Metabolite (3) Fungal (2) HCV (1) HCV Protease (1) Interleukin Related (3) Isotope-Labeled Compounds (9) MicroRNA (5) Orthopoxvirus (4) Reactive Oxygen Species (ROS) (1) Reference Standards (11) Topoisomerase (35)
By Research Areas:	Cancer (10) Infection (80) Inflammation/Immunology (9) Neurological Disease (3)

By Targets:

Bacterial (78)

DNA Glycosylase (1)

DNA/RNA Synthesis (39)

Antibiotic (44)

Apoptosis (2)

Cytochrome P450 (1)

Dihydrofolate reductase (DHFR) (1)

Drug Derivative (1)

Drug Metabolite (4)

Endogenous Metabolite (3)

Fungal (2)

HCV (1)

HCV Protease (1)

Interleukin Related (3)

Isotope-Labeled Compounds (9)

MicroRNA (5)

Orthopoxvirus (4)

Reactive Oxygen Species (ROS) (1)

Reference Standards (11)

Topoisomerase (35)

By Research Areas:

Cancer (10)

Infection (80)

Inflammation/Immunology (9)

Neurological Disease (3)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Bacterial DNA-PK DNA Glycosylase DNA Methyltransferase DNA Stain DNA Alkylator/Crosslinker DNA/RNA Synthesis

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0125

Ofloxacin 10+ Cited Publications Hoe-280	Bacterial Antibiotic Endogenous Metabolite Orthopoxvirus	Infection Cancer
Ofloxacin (Hoe-280) is a fluoroquinolone whose primary mechanism of action is inhibition of bacterial DNA gyrase. Ofloxacin shows inhibitory activity against vaccinia virus (VV).

HY-17028

Besifloxacin Hydrochloride	Bacterial Antibiotic DNA/RNA Synthesis Topoisomerase	Infection Inflammation/Immunology
Besifloxacin Hydrochloride is a fourth generation fluoroquinolone antibiotic. Besifloxacin Hydrochloride is a **DNA gyrase and topoisomerase IV inhibitor. Besifloxacin Hydrochloride has broad-spectrum antibacterial** activity, it is effective against Gram-negative and Gram-positive aerobic and anaerobic strains and reduces the incidence of drug resistance. Besifloxacin Hydrochloride has anti-inflammatory activity. Besifloxacin Hydrochloride can be used in bacterial conjunctivitis research .

HY-17647

Zoliflodacin 5+ Cited Publications ETX0914; AZD0914	DNA/RNA Synthesis Bacterial Antibiotic	Infection
Zoliflodacin (ETX0914;AZD0914) is a novel spiropyrimidinetrione **bacterial DNA gyrase/topoisomerase** inhibitor. Zoliflodacin has potent in vitro antibacterial activity against Gram-positive and Gram-negative organisms, including S. aureus with the MIC₉₀ of 0.25 μg/mL.

HY-10581

Gatifloxacin 4 Publications Verification AM-1155; BMS-206584; PD135432	Bacterial Topoisomerase Antibiotic	Infection Neurological Disease Cancer
Gatifloxacin (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic that can cross the blood-brain barrier, with broad-spectrum antibacterial activity. Gatifloxacin inhibits bacterial type II topoisomerases (IC₅₀=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli **DNA gyrase (IC₅₀*=0.109 μg/ml) . Gatifloxacin can be used to treat bacterial* conjunctivitis in vivo.

HY-B0506

Nadifloxacin 1 Publications Verification OPC7251	Bacterial Antibiotic DNA/RNA Synthesis Interleukin Related	Infection Inflammation/Immunology
Nadifloxacin (OPC7251) is a broad-spectrum quinolone antibiotic. Nadifloxacin inhibits bacterial DNA gyrase and topoisomerase IV, interfering with DNA replication. It also suppresses the production of proinflammatory cytokines (such as IL-1α, IL-6, and IL-8). Nadifloxacin exhibits antibacterial activity against various pathogens, including Propionibacterium acnes and Staphylococcus aureus. Nadifloxacin also exhibits anti-inflammatory activity. Nadifloxacin can be used in the research of skin infections such as acne vulgaris, folliculitis, and impetigo .

HY-W011117

Danofloxacin	Bacterial DNA/RNA Synthesis Antibiotic	Infection
Danofloxacin is an orally active quinolone antibiotic. Danofloxacin targets bacterial DNA gyrase and inhibits bacterial DNA replication, transcription and growth. Danofloxacin can be used for various bacterial infections caused by Escherichia coli, Mycoplasma and other pathogens .

HY-N7066

Difloxacin hydrochloride A-56619 hydrochloride	Bacterial DNA/RNA Synthesis	Infection
Difloxacin hydrochloride (A-56619 hydrochloride) is an orally active bactericidal agent. Difloxacin hydrochloride inhibits bacterial **DNA gyrase*. Difloxacin hydrochloride exhibits concentration-dependent bactericidal activity. Difloxacin hydrochloride shows strong in vitro activity against a variety of Gram-positive and Gram-negative bacteria. Difloxacin hydrochloride can be used in research related to colibacillosis and Staphylococcus aureus* infections .

HY-B0268A

Enoxacin hydrate 2 Publications Verification Enoxacin sesquihydrate; AT-2266 hydrate; CI-919 hydrate	Bacterial DNA/RNA Synthesis MicroRNA Antibiotic	Infection Cancer
Enoxacin hydrate (Enoxacin sesquihydrate), a fluoroquinolone, interferes with DNA replication and inhibits bacterial DNA gyrase (IC₅₀=126 µg/ml) and topoisomerase IV (IC₅₀=26.5 µg/ml). Enoxacin hydrate is a miRNA processing activator and enhances siRNA-mediated mRNA degradation and promotes the biogenesis of endogenous miRNAs. Enoxacin hydrate has potent activities against gram-positive and -negative bacteria. Enoxacin hydrate is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2 (TRBP)-mediated microRNA processing .

HY-B0268

Enoxacin 2 Publications Verification AT 2266; CI 919	Bacterial DNA/RNA Synthesis MicroRNA Antibiotic	Infection Cancer
Enoxacin (AT 2266), a fluoroquinolone, interferes with DNA replication and inhibits bacterial DNA gyrase (IC₅₀=126 µg/ml) and topoisomerase IV (IC₅₀=26.5 µg/ml). Enoxacin is a miRNA processing activator and enhances siRNA-mediated mRNA degradation and promotes the biogenesis of endogenous miRNAs. Enoxacin has potent activities against gram-positive and -negative bacteria. Enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2 (TRBP)-mediated microRNA processing .

HY-B0330B

Levofloxacin hydrochloride Maximum Cited Publications 35 Publications Verification (-)-Ofloxacin hydrochloride	Antibiotic Bacterial DNA/RNA Synthesis Topoisomerase Orthopoxvirus Apoptosis	Infection Neurological Disease Cancer
Levofloxacin hydrochloride is an orally active antibiotic. Levofloxacin inhibits **DNA gyrase and topoisomerase IV activity, inducing Apoptosis*. Levofloxacin hydrochloride has antibacterial activity against both Gram-positive and Gram-negative bacteria. Levofloxacin hydrochloride exhibits anticancer activity against lung cancer. Levofloxacin hydrochloride has anti-acnegenic, anxiogenic, and analgesic effects. Levofloxacin hydrochloride shortens sleep duration in mice. Levofloxacin hydrochloride can be used in the research of infectious diseases (such as tuberculosis, chronic periodontitis, bacterial* infections associated with stable COPD, and BK viremia) and lung cancer .

HY-Y0191

α-Pyridone 2-Pyridone	Endogenous Metabolite Bacterial	Infection
α-Pyridone (2-Pyridone) is an antibacterial agent that plays an important role in the field of biochemical research. α-Pyridone can serve as a scaffold compound to synthesize a variety of active compounds .

HY-10581A

Gatifloxacin hydrochloride 4 Publications Verification AM-1155 hydrochloride; BMS-206584 hydrochloride; PD135432 hydrochloride	Bacterial Topoisomerase Antibiotic	Infection
Gatifloxacin hydrochloride (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin hydrochloride inhibits bacterial type II topoisomerases (IC₅₀=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli **DNA gyrase (IC₅₀** = 0.109 μg/ml) . Gatifloxacin hydrochloride can be used to treat bacterial conjunctivitis in vivo.

HY-N1341

Roseoside	HCV HCV Protease DNA/RNA Synthesis Bacterial	Infection
Roseoside is an inhibitor of **DNA gyrase and HAV 3C protease, and also inhibits HCV NS5A/B replicase in human systems with an IC₅₀** of 20 μM. Roseoside binds to the active site of enzymes and stabilizes the interaction by forming hydrogen bonds with key amino acid residues. Roseoside inhibits the growth of Gram-positive bacteria, Gram-negative bacteria, and Candida albicans, and interferes with HCV RNA replication in vitro by inhibiting HCV NS5A/B replicase (IC₅₀=20 μM). Roseoside shows no cytotoxicity and serves as a research tool for studies related to bacterial infections, candidiasis, HAV and HCV .

HY-16742B

Gepotidacin mesylate hydrate 10+ Cited Publications	Antibiotic Bacterial Topoisomerase	Infection
Gepotidacin mesylate hydrate is an orally active triazaacenaphthylene antibiotic and bacterial type II topoisomerase inhibitor. Gepotidacin mesylate hydrate inhibits bacterial DNA replication by blocking topoisomerase enzymes. Gepotidacin mesylate hydrate selectively inhibits topoisomerase IV and the B subunit of DNA gyrase .

HY-B0330S

Levofloxacin-d8 (-)-Ofloxacin-d₈	Bacterial Antibiotic	Infection
Levofloxacin-d₈ is the deuterium labeled Levofloxacin. Levofloxacin, a synthetic fluoroquinolone, is an antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.

HY-162959

BWC0977	Bacterial Topoisomerase DNA/RNA Synthesis	Infection
BWC0977 is an antibacterial agent that inhibits bacterial DNA replication via inhibition of **DNA gyrase and topoisomerase IV*. BWC0977 exhibits a minimum inhibitory concentration (MIC₉₀) of 0.03-2 µg/mL against MDR (Multi-Drug Resistant) Gram-negative bacteria* .

HY-123515

Clorobiocin		Infection
Clorobiocin is an antibacterial agent with an IC₅₀ of 0.21 μM against the B subunit of E. coli DNA gyrase. Clorobiocin targets the mLaC protein of Gram-negative bacteria. Clorobiocin potently inhibits bacterial DNA replication. Clorobiocin can be used in studies on Gram-negative bacterial infections, such as Acinetobacter baumannii and E. coli infections .

HY-135389

Desmethyl Levofloxacin	Drug Metabolite Antibiotic	Infection
Desmethyl Levofloxacin is a metabolite of Levofloxacin. Levofloxacin, a synthetic fluoroquinolone, is an antibacterial agent that inhibits the supercoiling activity of bacterial **DNA gyrase*, halting DNA* replication .

HY-B0343C

Sarafloxacin hydrochloride 100 μg/mL in methanol 2 Publications Verification	Bacterial
Sarafloxacin hydrochloride 100 μg/mL in methanol is an antibiotic with activity to inhibit bacterial growth. Sarafloxacin hydrochloride 100 μg/mL in methanol is widely used in veterinary medicine to inhibit bacterial infections. The mechanism of action of Sarafloxacin hydrochloride 100 μg/mL in methanol is mainly achieved by inhibiting the activity of bacterial DNA gyrase. Sarafloxacin hydrochloride 100 μg/mL in methanol is also used in animal feed to improve feed conversion and promote growth.

HY-B0125R

Ofloxacin (Standard) Hoe-280 (Standard)	Reference Standards Bacterial Antibiotic Endogenous Metabolite Orthopoxvirus	Infection
Ofloxacin (Standard) is the analytical standard of Ofloxacin. This product is intended for research and analytical applications. Ofloxacin (Hoe-280) is a fluoroquinolone whose primary mechanism of action is inhibition of bacterial DNA gyrase. Ofloxacin shows inhibitory activity against vaccinia virus (VV).

HY-108988

Albicidin	Antibiotic Bacterial Topoisomerase DNA/RNA Synthesis	Infection
Albicidin is a peptide antibiotic with phytotoxic activity. Albicidin potently inhibits bacterial and plant **DNA gyrase** at nanomolar concentrations, blocks DNA replication, and exhibits excellent antibacterial efficacy against multidrug-resistant bacteria. Albicidin possesses bactericidal activity against Gram-positive and Gram-negative microorganisms, and acts as a virulence factor for the systemic plant infection by Xanthomonas albilineans. Albicidin can be used in studies related to bacterial infections and sugarcane leaf blight .

HY-B0330BR

Levofloxacin hydrochloride (Standard) (-)-Ofloxacin hydrochloride (Standard)	Reference Standards Antibiotic Bacterial DNA/RNA Synthesis Topoisomerase Orthopoxvirus Apoptosis	Infection Neurological Disease Cancer
Levofloxacin (hydrochloride) (Standard) is the analytical standard of Levofloxacin hydrochloride (HY-B0330B). This product is intended for research and analytical applications. Levofloxacin hydrochloride is an orally active antibiotic. Levofloxacin inhibits **DNA gyrase and topoisomerase IV activity, inducing Apoptosis*. Levofloxacin hydrochloride has antibacterial activity against both Gram-positive and Gram-negative bacteria. Levofloxacin hydrochloride exhibits anticancer activity against lung cancer. Levofloxacin hydrochloride has anti-acnegenic, anxiogenic, and analgesic effects. Levofloxacin hydrochloride shortens sleep duration in mice. Levofloxacin hydrochloride can be used in the research of infectious diseases (such as tuberculosis, chronic periodontitis, bacterial* infections associated with stable COPD, and BK viremia) and lung cancer .

HY-175539

DNA gyrase/Topo IV-IN-2	Bacterial Topoisomerase DNA/RNA Synthesis	Infection
DNA gyrase/Topo IV-IN-2 (Compound AK19) is an antibacterial agent with IC₅₀ values of 0.783 μM and 7.136 μM against E. coli **DNA gyrase and topoisomerase IV*, respectively. DNA* gyrase/Topo IV-IN-2 exhibits broad-spectrum antibacterial efficacy against both Gram-positive and Gram-negative pathogens. DNA gyrase/Topo IV-IN-2 can inhibit the biofilms of B. subtilis and MRSA, with an MIC of 1.9 μM against both B. subtilis and MRSA. DNA gyrase/Topo IV-IN-2 can be used in research related to anti-drug-resistant bacterial drugs .

HY-101472

Closthioamide	Bacterial	Infection
Closthioamide is a potent inhibitor of bacterial DNA gyrase and highly active against Ec, MRSA, VRE and Mv), with MICs of 9.00 μM, 0.58 μM, 0.58 μM and 72.03 μM respectively.

HY-B0125S1

Ofloxacin-d8	Bacterial Antibiotic	Infection
Ofloxacin-d₈ (Hoe-280-d8) is the deuterium labeled Ofloxacin. Ofloxacin (Hoe-280) is a fluoroquinolone whose primary mechanism of action is inhibition of bacterial DNA gyrase.

HY-162959A

BWC0977 formic	Bacterial Topoisomerase DNA/RNA Synthesis	Infection
BWC0977 formic is an antibacterial agent that inhibits bacterial DNA replication via inhibition of **DNA gyrase and topoisomerase IV*. BWC0977 formic exhibits a minimum inhibitory concentration (MIC₉₀) of 0.03-2 µg/mL against MDR (Multi-Drug Resistant) Gram-negative bacteria* .

HY-10581C

Gatifloxacin sesquihydrate AM-1155 sesquihydrate; BMS-206584 sesquihydrate; PD135432 sesquihydrate	Bacterial Topoisomerase Antibiotic	Infection Inflammation/Immunology
Gatifloxacin sesquihydrate (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin sesquihydrate inhibits bacterial type II topoisomerases (IC₅₀=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli **DNA gyrase (IC₅₀** = 0.109 μg/ml) . Gatifloxacin sesquihydrate can be used to treat bacterial conjunctivitis in vivo.

HY-115990

Topoisomerase IV inhibitor 1	Topoisomerase Bacterial	Infection
Topoisomerase IV inhibitor 2 (compound 7d) is a potent DNA topoisomerase IV (TOPO IV) inhibitor with IC₅₀s of 0.23 μM and 0.43 μM for TOPO IV and DNA gyrase, respectively. Topoisomerase IV inhibitor 2 has anti-bacterial activity, with MICs of 0.972 μM and 0.608 μM in Staphylococcus aureus Newman and Escherichia coli ATCC8739, respectively .

HY-143483

NBTIs-IN-5	Bacterial	Infection
NBTIs-IN-5 (Compound 5r) is a NBTI (Novel Bacterial Topoisomerase Inhibitor) **DNA gyrase inhibitor with an IC₅₀** of 1.5 μM against Mycobacterium abscessus (Mabs) DNA gyrase. NBTIs-IN-5 inhibits Mabs bamboo bacterial growth with an MIC₉₀ of 0.4 μM .

HY-B0268S1

Enoxacin-d8 hydrochloride	Isotope-Labeled Compounds Bacterial DNA/RNA Synthesis MicroRNA Antibiotic	Infection Cancer
Enoxacin-d₈ (hydrochloride) is deuterium labeled Enoxacin. Enoxacin (AT 2266), a fluoroquinolone, interferes with DNA replication and inhibits bacterial DNA gyrase (IC₅₀=126 μg/ml) and topoisomerase IV (IC₅₀=26.5 μg/ml). Enoxacin is a miRNA processing activator and enhances siRNA-mediated mRNA degradation and promotes the biogenesis of endogenous miRNAs. Enoxacin has potent activities against gram-positive and -negative bacteria. Enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2 (TRBP)-mediated microRNA processing .

HY-141442

Dihydronovobiocin	Bacterial Antibiotic	Infection
Dihydronovobiocin is a *bacterial* inhibitor and ATPase inhibitor that can bind to GyrB. Dihydronovobiocin can be used to study the interaction between coumarin antibiotics (such as Novobiocin, Chlorobiocin, and Coumermycin) and DNA gyrase. Dihydronovobiocin also has the potential to study bacterial infections .

HY-172264

XT17	Antibiotic Bacterial DNA/RNA Synthesis	Infection
XT17 is an anthrone compound with broad-spectrum antibacterial activity. It exerts its antibacterial effect by disrupting the cell wall and inhibiting DNA synthesis. XT17 exhibits weak hemolytic activity, low cytotoxicity against mammalian cell lines, and a low frequency of drug resistance. Meanwhile, XT17 shows in vivo efficacy in a mouse corneal infection model induced by Staphylococcus aureus or Pseudomonas aeruginosa. Further docking studies have confirmed that XT17 can form a stable complex with **bacterial gyrase**. XT17 can be used in the research of the anti - infection field .

HY-143484

844-TFM	Bacterial	Infection
844-TFM is a NBTI (novel bacterial topoisomerase inhibitor) **DNA gyrase inhibitor, with an IC₅₀** of 1.5 μM. 844-TFM exhibits bactericidal properties against M. abscessus .

HY-174227

Topoisomerase inhibitor 6	Topoisomerase Bacterial	Infection
Topoisomerase inhibitor 6 (Compound REDX05931) is a dual irreversible inhibitor of **DNA gyrase and topoisomerase IV (MIC*=0.06 μg/mL against fluoroquinolone-resistant S. aureus). Topoisomerase inhibitor 6 blocks DNA* strand break-reunion, inducing lethal DNA damage. Topoisomerase inhibitor 6 is promising for research of Gram-positive bacterial infections (e.g., S. aureus, S. pneumoniae) .

HY-117657

(-)-BO 2367	Topoisomerase Bacterial	Inflammation/Immunology Cancer
(-)-BO 2367, an antimicrobial quinolone, is a strong mammalian and bacterial topoisomerase II inhibitor. (-)-BO 2367 shows IC₅₀ values with 3.8 μM, 0.5 μM, and 1 μM against the DNA relaxation activity of L1210 topoisomerase II and the supercoiling activities of Escherichia coli gyrase and Micrococcus luteus gyrase, respectively. (-)-BO 2367 is a potent antitumor agent .

HY-161364

Antibacterial agent 200	Bacterial	Inflammation/Immunology
Antibacterial agent 200 (pyridyl HH 7), a unique hydrazyl hydroxycoumarin (HH), has strong antibacterial efficacy and broad antibacterial spectrum with MIC values ranging from 0.5 to 32 μg/mL for Gram-positive and Gram-negative bacteria. Antibacterial agent 200 exhibits a good inhibition against Pseudomonas aeruginosa 27853 with a low MIC value of 0.5 μg/mL. Antibacterial agent 200 can eradicate the integrity of bacterial membrane, result in the leakage of intracellular proteins, and interact with bacterial DNA gyrase via non-covalent binding .

HY-149379

DNA gyrase B-IN-3	Bacterial DNA/RNA Synthesis	Infection
DNA gyrase B-IN-3 (Compound A) is a bacterial DNA gyrase B inhibitor (IC₅₀: < 10 nM). DNA gyrase B-IN-3 has antibacterial activity against gram-positive strains .

HY-168648

DNA Gyrase/DHFR-IN-1	Bacterial Fungal Dihydrofolate reductase (DHFR)	Infection
DNA Gyrase/DHFR-IN-1 is a dual inhibitor of bacterial **DNA gyrase and DHFR*, with IC₅₀s of 182 μM and 3.90 μM for E. coli DNA* gyrase and DHFR respectively. DNA Gyrase/DHFR-IN-1 has bactericidal and antifungal activity .

HY-147818

DNA Gyrase-IN-2	Bacterial DNA/RNA Synthesis	Infection
DNA Gyrase-IN-2 (Compound 22a) is a bacterial DNA gyrase B inhibitor with IC₅₀s of 3.29-10.49 and 4.41-5.61 µM for E. coli DNA gyrase and M. tuberculosis DNA gyrase. Anti-tubercular and antibacterial activity .

HY-147819

DNA Gyrase-IN-3	Bacterial DNA/RNA Synthesis	Infection
DNA Gyrase-IN-3 (Compound 28) is a bacterial DNA gyrase B inhibitor with IC₅₀s of 5.41-15.64 µM for E. coli DNA gyrase. Anti-tubercular and antibacterial activity .

HY-172962

DNA Gyrase-IN-17	DNA/RNA Synthesis Bacterial	Infection
DNA Gyrase-IN-17 (Compound 5C) is a **DNA Gyrase** inhibitor. DNA Gyrase-IN-17 exhibits significant antibacterial activity against a variety of Gram-positive and Gram-negative strains (such as Enterococcus faecalis, Escherichia coli, Pseudomonas aeruginosa, etc.), with a MIC value of 62.5 μg/mL. DNA Gyrase-IN-17 interferes with DNA replication by inhibiting bacterial DNA gyrase. DNA Gyrase-IN-17 can be used in the development of antibacterial drugs, especially for the study of drug-resistant strains .

HY-169384

Antimycobacterial agent-10	Bacterial	Infection
Antimycobacterial agent-10 (compound 5) is a **DNA gyrase** inhibitor with anti-bacterial actiity (IC₅₀=96 nM, M. tuberculosis gyrase).

HY-N7066R

Difloxacin hydrochloride (Standard) A-56619 hydrochloride (Standard)	Reference Standards Bacterial Antibiotic	Infection
Difloxacin (hydrochloride) (Standard) is the analytical standard of Difloxacin (hydrochloride). This product is intended for research and analytical applications. Difloxacin hydrochloride is a broad-spectrum antibacterial agent. Difloxacin hydrochloride inhibits bacterial DNA gyrase and exhibits a concentration-dependant bactericidal effect by interference with the activity of DNA gyrase and topoisomerase IV .

HY-155007

DNA gyrase B-IN-2	Bacterial	Infection
DNA gyrase B-IN-2 (Compound E) is a 2-aminobenzothiazole-based DNA gyrase B inhibitor with promising activity against ESKAPE bacterial pathogens. DNA gyrase B-IN-2 showed low nanomolar inhibition of DNA gyrase (IC₅₀ < 10 nM) and broad-spectrum antibacterial activity against pathogens belonging to the ESKAPE group, with the minimum inhibitory concentration < 0.03 μg/mL for most Gram-positive strains and 4–16 μg/mL against Gram-negative E. coli, Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae.DNA gyrase B-IN-2 can be used for the research of infection .

HY-W011117S

Danofloxacin-d3	Isotope-Labeled Compounds Bacterial DNA/RNA Synthesis Antibiotic	Infection
Danofloxacin-d₃ is deuterium labeled Danofloxacin. Danofloxacin is an orally active quinolone antibiotic. Danofloxacin targets bacterial DNA gyrase and inhibits bacterial DNA replication, transcription and growth. Danofloxacin can be used for various bacterial infections caused by Escherichia coli, Mycoplasma and other pathogens.

HY-B0330S1

(S)-Ofloxacin-d3	Bacterial Antibiotic	Infection
(S)-Ofloxacin-d₃ is the deuterium labeled Levofloxacin. Levofloxacin, a synthetic fluoroquinolone, is an antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.

HY-W011117S1

Danofloxacin-d3-1	Isotope-Labeled Compounds Bacterial DNA/RNA Synthesis Antibiotic	Infection
Danofloxacin-d3-1 is deuterium labeled Danofloxacin. Danofloxacin is an orally active quinolone antibiotic. Danofloxacin targets bacterial DNA gyrase and inhibits bacterial DNA replication, transcription and growth. Danofloxacin can be used for various bacterial infections caused by Escherichia coli, Mycoplasma and other pathogens.

HY-W011117R

Danofloxacin (Standard)	Reference Standards Bacterial DNA/RNA Synthesis Antibiotic	Infection
Danofloxacin (Standard) is the analytical standard of Danofloxacin. This product is intended for research and analytical applications. Danofloxacin is an orally active quinolone antibiotic. Danofloxacin targets bacterial DNA gyrase and inhibits bacterial DNA replication, transcription and growth. Danofloxacin can be used for various bacterial infections caused by Escherichia coli, Mycoplasma and other pathogens.

HY-135389S

Desmethyl Levofloxacin-d8 hydrochloride	Isotope-Labeled Compounds Drug Metabolite Antibiotic	Infection
Desmethyl Levofloxacin-d8 hydrochloride is the deuterium labeled Desmethyl Levofloxacin. Desmethyl Levofloxacin is a metabolite of Levofloxacin. Levofloxacin, a synthetic fluoroquinolone, is an antibacterial agent that inhibits the supercoiling activity of bacterial **DNA gyrase*, halting DNA* replication .

HY-135389S1

Desmethyl Levofloxacin-d8	Isotope-Labeled Compounds Drug Metabolite Antibiotic	Infection
Desmethyl Levofloxacin-d₈ is deuterium labeled Desmethyl Levofloxacin. Desmethyl Levofloxacin is a metabolite of Levofloxacin. Levofloxacin, a synthetic fluoroquinolone, is an antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B0125

Ofloxacin 10+ Cited Publications Hoe-280	Infection Classification of Application Fields Ketones, Aldehydes, Acids Endogenous metabolite Disease Research Fields Source Classification	Bacterial Antibiotic Endogenous Metabolite Orthopoxvirus
Ofloxacin (Hoe-280) is a fluoroquinolone whose primary mechanism of action is inhibition of bacterial DNA gyrase. Ofloxacin shows inhibitory activity against vaccinia virus (VV).

HY-Y0191

α-Pyridone 2-Pyridone	Structural Classification Natural Products Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite Bacterial
α-Pyridone (2-Pyridone) is an antibacterial agent that plays an important role in the field of biochemical research. α-Pyridone can serve as a scaffold compound to synthesize a variety of active compounds .

HY-B0125R

Ofloxacin (Standard) Hoe-280 (Standard)	Structural Classification Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Reference Standards Bacterial Antibiotic Endogenous Metabolite Orthopoxvirus
Ofloxacin (Standard) is the analytical standard of Ofloxacin. This product is intended for research and analytical applications. Ofloxacin (Hoe-280) is a fluoroquinolone whose primary mechanism of action is inhibition of bacterial DNA gyrase. Ofloxacin shows inhibitory activity against vaccinia virus (VV).

HY-101472

Closthioamide	Infection Microorganisms Classification of Application Fields Antibiotics Phenols Polyphenols Antibacterial Disease Research Disease Research Fields Other Antibiotics Source Classification	Bacterial
Closthioamide is a potent inhibitor of bacterial DNA gyrase and highly active against Ec, MRSA, VRE and Mv), with MICs of 9.00 μM, 0.58 μM, 0.58 μM and 72.03 μM respectively.

HY-141442

Dihydronovobiocin	Microorganisms Antibiotics Other Antibiotics Source Classification	Bacterial Antibiotic
Dihydronovobiocin is a *bacterial* inhibitor and ATPase inhibitor that can bind to GyrB. Dihydronovobiocin can be used to study the interaction between coumarin antibiotics (such as Novobiocin, Chlorobiocin, and Coumermycin) and DNA gyrase. Dihydronovobiocin also has the potential to study bacterial infections .

HY-114604

Propioxatin B	Natural Products Microorganisms Source Classification	Bacterial
Propioxatin B is a tricyclic sesquiterpenoid compound isolated from the root of vetiver grass. It has anti-tuberculosis activity and inhibitory effects on a variety of drug-resistant mutants of Mycobacterium tuberculosis. In computer simulation docking studies, it showed binding affinity with bacterial DNA gyrase and has a certain safety in vivo.

Cat. No.	Product Name	Chemical Structure

HY-B0330S

Levofloxacin-d8
Levofloxacin-d₈ is the deuterium labeled Levofloxacin. Levofloxacin, a synthetic fluoroquinolone, is an antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.

HY-B0125S1

Ofloxacin-d8
Ofloxacin-d₈ (Hoe-280-d8) is the deuterium labeled Ofloxacin. Ofloxacin (Hoe-280) is a fluoroquinolone whose primary mechanism of action is inhibition of bacterial DNA gyrase.

HY-B0268S1

Enoxacin-d8 hydrochloride

Enoxacin-d₈ (hydrochloride) is deuterium labeled Enoxacin. Enoxacin (AT 2266), a fluoroquinolone, interferes with DNA replication and inhibits bacterial DNA gyrase (IC₅₀=126 μg/ml) and topoisomerase IV (IC₅₀=26.5 μg/ml). Enoxacin is a miRNA processing activator and enhances siRNA-mediated mRNA degradation and promotes the biogenesis of endogenous miRNAs. Enoxacin has potent activities against gram-positive and -negative bacteria. Enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2 (TRBP)-mediated microRNA processing .

HY-W011117S

Danofloxacin-d3
Danofloxacin-d₃ is deuterium labeled Danofloxacin. Danofloxacin is an orally active quinolone antibiotic. Danofloxacin targets bacterial DNA gyrase and inhibits bacterial DNA replication, transcription and growth. Danofloxacin can be used for various bacterial infections caused by Escherichia coli, Mycoplasma and other pathogens.

HY-B0330S1

(S)-Ofloxacin-d3
(S)-Ofloxacin-d₃ is the deuterium labeled Levofloxacin. Levofloxacin, a synthetic fluoroquinolone, is an antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.

HY-W011117S1

Danofloxacin-d3-1
Danofloxacin-d3-1 is deuterium labeled Danofloxacin. Danofloxacin is an orally active quinolone antibiotic. Danofloxacin targets bacterial DNA gyrase and inhibits bacterial DNA replication, transcription and growth. Danofloxacin can be used for various bacterial infections caused by Escherichia coli, Mycoplasma and other pathogens.

HY-135389S

Desmethyl Levofloxacin-d8 hydrochloride
Desmethyl Levofloxacin-d8 hydrochloride is the deuterium labeled Desmethyl Levofloxacin. Desmethyl Levofloxacin is a metabolite of Levofloxacin. Levofloxacin, a synthetic fluoroquinolone, is an antibacterial agent that inhibits the supercoiling activity of bacterial **DNA gyrase*, halting DNA* replication .

HY-135389S1

Desmethyl Levofloxacin-d8
Desmethyl Levofloxacin-d₈ is deuterium labeled Desmethyl Levofloxacin. Desmethyl Levofloxacin is a metabolite of Levofloxacin. Levofloxacin, a synthetic fluoroquinolone, is an antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication .

HY-10581AS

Gatifloxacin-d3 hydrochloride

Gatifloxacin-d₃ (hydrochloride) is the deuterium labeled Gatifloxacin (hydrochloride). Gatifloxacin hydrochloride (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin hydrochloride inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50 = 0.109 μg/ml). Gatifloxacin hydrochloride can be used to treat bacterial conjunctivitis in vivo.

HY-W700069

Gatifloxacin-d4

Gatifloxacin-d₄ (AM-1155-d₄) is the deuterium labeled Gatifloxacin (HY-10581). Gatifloxacin (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin inhibits bacterial type II topoisomerases (IC₅₀ = 13.8 μg/mL for S. aureus topoisomerase IV) and E.coli DNA gyrase (IC₅₀ = 0.109 μg/mL) . Gatifloxacin can be used for the study of bacterial conjunctivitis in vivo.

HY-B0268S2

Enoxacin-d8 hydrate

Enoxacin-d₈ (hydrate) is deuterium labeled Enoxacin. Enoxacin (AT 2266), a fluoroquinolone, interferes with DNA replication and inhibits bacterial DNA gyrase (IC₅₀=126 μg/ml) and topoisomerase IV (IC₅₀=26.5 μg/ml). Enoxacin is a miRNA processing activator and enhances siRNA-mediated mRNA degradation and promotes the biogenesis of endogenous miRNAs. Enoxacin has potent activities against gram-positive and -negative bacteria. Enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2 (TRBP)-mediated microRNA processing .

HY-B0506S1

Nadifloxacin-d5

Nadifloxacin-d₅ (OPC7251-d₅) is deuterium labeled Nadifloxacin (HY-B0506). Nadifloxacin (OPC7251) is a broad-spectrum quinolone antibiotic. Nadifloxacin inhibits bacterial DNA gyrase and topoisomerase IV, interfering with DNA replication. It also suppresses the production of proinflammatory cytokines (such as IL-1α, IL-6, and IL-8). Nadifloxacin exhibits antibacterial activity against various pathogens, including Propionibacterium acnes and Staphylococcus aureus. Nadifloxacin also exhibits anti-inflammatory activity. Nadifloxacin can be used in the research of skin infections such as acne vulgaris, folliculitis, and impetigo .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks